tradingkey.logo
tradingkey.logo
Search

Eton Pharma rises after US FDA accepts application for hormone disorder drug

ReutersJul 8, 2025 12:13 PM
facebooktwitterlinkedin
View all comments0

Shares of drugmaker Eton Pharmaceuticals ETON.O rise 3.5% to $14.90 premarket

Co says the US FDA has accepted its application for potential approval of its drug candidate ET-600

If approved, ET-600 is expected to be the only oral liquid option on the market for central diabetes insipidius, ETON says

Central diabetes insipidius is a condition where the body doesn't produce enough vasopressin, a hormone that regulates water balance by signaling kidneys to conserve water

The FDA will give its decision on ET-600 on or before February 26, 2026

Up to last close, stock had risen 8% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI